A. M. Davis

Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.

K. Moore, L. Dockery, K. Ding, 2019, Gynecologic oncology.

Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.

L. Dockery, K. Ding, R. Arend, 2019, Gynecologic oncology.

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.

D. Provencher, M. Birrer, I. Vergote, 2019, Gynecologic oncology.